By René Roy (Eds.)
content material: Preface --
T-cell immunity of carbohydrates / Luis Pena Icart ... [et al.] --
The regulatory framework for glycoconjugate vaccines / Christopher Jones --
Conjugation tools in the direction of man made vaccines / V. Pozsgay and J. Kubler-Kielb --
Haemophilus influenzae sort b conjugate vaccine with an artificial capsular polysaccharide antigen : chemical view / Vicente Verez Bencomo ... [et al.] --
Immunology of experimental artificial carbohydrate-protein conjugate vaccines opposed to Streptococcus pneumoniae serotypes / damage Snippe, Wouter T.M. Jansen, and Johannis P. Kamerling --
From epitope characterization to the layout of semi-synthetic glycoconjugate vaccines opposed to Shigella flexneri 2a an infection / Laurence A. Mulard and Armelle Phalipon --
automatic oligosaccharide synthesis to create vaccines for malaria and different parasites / Bridget L. Stocker, Alexandria Hölemann, and Peter H. Seeberger --
A uniquely small, protecting carbohydrate epitope may well yield a conjugate vaccine for Candida albicans / David R. package ... [et al.] --
stories towards the improvement of anti-tuberculosis vaccines according to mycobacterial lipoarabinomannan / Hyo-Sun Kim ... [et al.] --
The lipoarabinomannan glycolipid of Mycobacterium tuberculosis : growth in overall synthesis through n-pentenyl orthoesters / Bert Fraser-Reid ... [et al.] --
Lipopolysaccharide antigens of Chlamydia / P. Kosma, H. Brade, and S.V. Evans --
man made carbohydrate-based antitumor vaccines / Rebecca M. Wilson ... [et al.] --
artificial glycopeptides for the development of anticancer vaccines / Horst Kunz ... [et al.] --
Glycopeptide dependent melanoma vaccines : the guideline of synthesis and structural definition / R. Rao Koganty, Damayanthi Yalamati, and Zi-Hua Jiang --
Peptide mimics of bacterial polysaccharides : power for discriminating vaccines / Silvia Borrelli ... [et al.].
Read or Download Carbohydrate-Based Vaccines PDF
Best immunology books
Even supposing the application of human antibodies as scientific therapeutics for melanoma and immune illnesses has been well-established, it is just commencing to be learned for the remedy of viral infectious ailments. Polyclonal immunoglobulins have lengthy been used for a few viral illnesses, yet they've got constrained efficiency and illness scope.
Research of multidirectional immunological responses on the tumor web site permits forming a brand new thought of The Tumor Immunoenvironment, that's brought and mentioned within the current booklet with a specific specialize in the function of immune cells in controlling the tumor microenvironment at varied phases of melanoma improvement.
Antibodies in phone Biology makes a speciality of a brand new iteration of protocols aimed toward the mobilephone biologist. This laboratory guide positive aspects structures and methods which are particularly proper for contemporary difficulties. The contributing authors were rigorously selected for his or her particular services, and feature supplied specific protocols, recipes, and troubleshooting courses in every one bankruptcy.
- Experimental Glycoscience: Glycobiology
- BRS Microbiology and Immunology (Board Review Series) (6th Edition)
- Lasso Peptides: Bacterial Strategies to Make and Maintain Bioactive Entangled Scaffolds
- The Immune Synapse: Methods and Protocols
Additional resources for Carbohydrate-Based Vaccines
Yewdell, J. ; Bennink, J. R. Nature 2000, 404, 770-774. 5. Reits, Ε. ; Drijfhout, J. ; Neefjes, J. Immunity 2003, 18, 97-108. 6. Garcia, K. ; Wilson, I. A. Annu. Rev. Immunol. 1999, 17, 369397. 7. S. C. G. C. Nature. 1994, 368, 215-221. 8. ; Vestberg, M . ; Holmdahl, R. Eur. J. Immunol. 1998, 28, 755-767. 9. ; Salvador, L. A. Methods Enzymol. 1997, 289, 221-45 10. Carbone, F. ; Gleeson, P. A. Glycobiology 1997, 7, 725-730. 18 11. Rudd, P. ; Wilson, I. ; Dwek, R. A. Science 2001, 291, 2370-2376.
Experience indicates that a wide variety of structural types can lead to effective glycoconjugate vaccines, although the detailed responses differ (1). These can be described as neo-glycoconjugate, crosslinked network or vesicle vaccines, which are illustrated in Figure 1. e. that the proposed molecule will elicit protective immunity), developing and validating assays, optimizing immunogenicity as determined by functional antibody assays, and assessing the quality of the antibody response (antibody isotype, Τ cell involvement and specificity) (25).
In the glycoconjugate vaccine field, there is ongoing concern that elimination of carriage of "vaccine" serotypes will lead to their replacement by "non-vaccine" serotypes, resulting in disease rates dropping initially but increasing again due to serotype replacement. Immunisation of infants and young children with pneumococcal glycoconjugates led to significant reductions in the incidence of disease due to vaccine serotypes in unvaccinated populations 30 - parents and grandparents. This probably reflects reduced carriage by children diminishing transmission to those with whom they are in daily contact (4).